The 2025 ASBMR Symposium and the ASBMR/RBDA 2025 Symposium will be held on Thursday, September 4, 2025, one day prior the 2025 Annual Meeting, at the Seattle Convention Center in Seattle, Washington, USA. Learn more about the goals of each meeting and view the full program.
2025 ASBMR Symposium on Musculoskeletal Impact of Immune and Skeletal Cells Crosstalk: Bench to Bedside
2025 ASBMR/RBDA Symposium on Rare Bone Diseases: From the Genome to the Lived Experience
Organized by Laura Calvi, M.D. and Natalie Sims, Ph.D., the goal of the 2025 ASBMR Symposium on Musculoskeletal Impact of Immune and Skeletal Cells Crosstalk: Bench to Bedside is to to discuss novel interactions between immune cell populations and skeletal cells that impact musculoskeletal health, including pathogenesis of rheumatologic, infectious and age-associated disorders, in order to envision future therapeutic, analytical and diagnostic tools.
- Session 1: Reciprocal Interactions of Skeletal and Immune Cells
- Session 2: Musculoskeletal Impact of Immune Cells
- Session 3: Pathogenesis of Cancer and Age-associated Disorders
- Session 4: Future Therapeutic, Analytical and Diagnostic Tools
| 8:00 am - 8:30 am |
Continental Breakfast |
| Session 1: Reciprocal Interactions of Skeletal and Immune Cells |
| 8:30 am - 8:40 am |
Introduction |
Laura Calvi and Natalie Sims |
| 8:40 am - 9:05 am |
Neutrophil Progenitors: Protecting the Skeleton From Their Home in the Marrow |
Natalie Sims |
| 9:05 am - 9:30 am |
Reciprocal suppression between TGFβ signaling and TNF stimulation finetunes the macrophage inflammatory response |
Baohong Zhao |
| 9:30 am - 9:45 am |
Macrophage Efferocytosis impacts the skeleton |
Lena Batoon |
| 9:45 am - 10:00 am |
Break |
| Session 2: Musculoskeletal Impact of Immune Cells |
| 10:00 am - 10:25 am |
Skeletal and Hematopoietic Consequences of Efferocytosis of Apoptotic Cells in the Bone Marrow |
Laura Calvi |
| 10:25 am - 10:50 am |
Role of a tubular lysosomal network in osteoclast function |
Nathan Pavlos |
| 10:50 am - 11:15 am |
TNF- induced activation of Schnurri 3 in osteoblasts contributes to systemic and articular bone loss by suppressing bone formation and enhancing osteoclast development |
Jae-Hyuck Shim |
| 11:15am - 11:30 am |
Gut microbiota drive Immune Reconstitution Bone Loss during Antiretroviral Therapy against HIV, through Antigen-Dependent T Cell activation |
Ashish Tripathi |
| 11:30 am - 1:00 pm |
Lunch and poster viewing |
| Session 3: Pathogenesis of Cancer and Age-Associated Disorders |
| 1:00 pm - 1:25 pm |
DKK1 creates a tumor-supporting environment through the suppression of NK cells during breast cancer progression |
Roberta Faccio |
| 1:25 pm - 1:50 pm |
Neutrophil anti-tumor responses against bone metastatic prostate cancer: mechanisms and therapeutic opportunities |
Leah Cook |
| 1:50 pm - 2:15 pm |
Clonal hematopoiesis and its impact on the aging osteo-hematopoietic (CHIP, MDS and its implication on bone health) |
Lorenz Hofbauer |
| 2:15 pm - 2:30 pm |
An inflammatory osteoblast niche marks blood cancer progression and promotes malignant stem cell stemness and expansion through serum amyloid A1 |
Pallavi Budgude |
| 2:30 pm - 3:00 pm |
Break |
| Session 4: Future Therapeutic, Analytical and Diagnostic Tools |
| 3:00 pm - 3:25 pm |
Role of RANKL/osteoclasts in Fibrous Dysplasia |
Julia Charles |
| 3:25 pm - 4:05 pm |
Translation opportunities in osteomyelitis |
Edward Schwarz |
| 3:50 pm - 4:05 pm |
BIG2-mediated dual inhibition of TNF? and IL-1? signaling ameliorates osteoarthritis in mouse and mynomolgus macaque models |
Wenyu Fu |
| 4:00 pm - 6:00 pm |
Combined Pre-Meeting Symposia reception and poster viewing |
Organized by Leanne Ward, Ph.D. and Erik Imel, M.D., with guidance from Outi Makitie, Lynda Bonewald, Wolfgang Hogler, and Chelsey Grimbly, the goal of the 2025 ASBMR/RBDA Symposium on Rare Bone Diseases: From the Genome to the Lived Experience is to gather experts in rare bone diseases to promote interactions among basic, translational and clinical researchers and discuss the latest advances on skeletal dysplasias, disorders of ectopic mineralization, prevention of muscle and bone loss and the diagnosis and treatment of rare bone diseases.
- Session 1: Skeletal Dysplasias
- Session 2: Disorders of Ectopic Mineralization
- Session 3: Prevention of Muscle and Bone Loss
- Session 4: From the Genome to the Lived Experience
| 7:30 am - 8:00 am |
Continental Breakfast |
| Session 1: Skeletal Dysplasis |
| 8:00 am - 8:10 am |
Introduction and Overview |
Leanne Ward and Erik Imel |
| 8:10 am - 8:15 am |
Rare Bone Scientific Interest Group (SIG) Introduction |
Fayez Safai and Martine Cohen-Solal |
| 8:15 am - 8:40 am |
Osteoclast-Osteoblast Feedback in Fibrous Dysplasia: Insights from Bench and Bedside |
Luis de Castro |
| 8:40 am - 9:05 am |
Novel Treatment Approaches in Fibrous Dysplasia |
Alison Boyce |
| 9:05 am - 9:30 am |
New, Disruptive Precision Therapies for Achondroplasia: Changing the Rules of the Game |
Ravi Savarirayan |
| 9:30 am - 9:45 am |
Effect of Long-Term Vosoritide Treatment in Pediatric Participants With Achondroplasia on Bone Mineral Density and Bone Content: Results From Quantitative Computed Tomography Analyses |
Klaus Engelke |
| 9:45 am - 10:00 am |
Break |
| Session 2: Disorders of Ectopic Mineralization |
| 10:00 am - 10:25 am |
Overview of the Pathophysiology of ENPP1 Deficiency |
David Weber |
| 10:25 am - 10:50 am |
Hyperphosphatemic Familial Tumoral Calcinosis: Defining Mechanisms to Inform Treatment |
Kelly Roszko |
| 10:50 am - 11:15 am |
Emerging Therapies for Fibrodysplasia Ossificans Progressive |
Edward Hsiao |
| 11:15 am - 11:40 am |
XLH and Enthesopathy |
Eva Liu |
| 11:40 am - 11:55 am |
Vantictumab, an anti-FZD antibody, Rescues the Osteopetrotic Bone Phenotype in Heterozygous ADO Mice |
Imranul Alam |
| 12:00 pm - 1:00 pm |
Lunch and poster viewing |
| Session 3: Prevention of Muscle and Bone Loss |
| 1:00 pm - 1:25 pm |
Mechanisms of Carpo-Tarsal Osteolysis from Pre-Clinical Models |
Roland Baron |
| 1:25 pm - 1:50 pm |
Clinical studies of vamorolone: An anti-inflammatory corticosteroid with unique structure/activity relationships: not metabolized by HSD11B's, and a MR antagonist |
Erik Hoffman |
| 1:50 pm - 2:15 pm |
Navigating Advocacy for Individuals with Duchenne Muscular Dystrophy in an Ever-Broadening Therapeutic Landscape |
Pat Furlong |
| 2:15 pm - 2:30 pm |
Duchenne Muscular Dystrophy leads to Concurrent Muscle and Bone Disease with a Loss of Osteoblastic Bone Cell Populations |
Amy Sato |
| 2:30 pm - 2:45 pm |
Break |
| Session 4: From the Genome to the Lived Experience |
| 2:45 pm - 3:10 pm |
Anti-Sclerostin Antibody for the Treatment of Osteogenesis Imperfecta |
Ken Kozloff |
| 3:10 pm - 3:35 pm |
Expanding Molecular Diagnoses in Rare Bone Disorders |
Frank Rauch |
| 3:35 pm - 4:00 pm |
Achondroplasia |
Colleen Gioffreda |
| 4:15 pm - 4:30 pm |
The Importance of Partnerships in Rare Bone Disease Research |
Tracy Hart |
| 4:30 pm - 6:00 pm |
Combined Pre-Meeting Symposia reception and poster viewing |
The ASBMR gratefully acknowledges the following companies for their educational grant support: Alexion, AstraZeneca Rare Disease, Ascendis Pharma, BioMarin Pharmaceutical Inc., BridgeBio Pharma, Inc., Inozyme Pharma, Ipsen Biopharmaceuticals Inc., Kyowa Kirin, Inc., and Ultragenyx Pharmaceutical Inc.